Skip to main
GYRE

GYRE Stock Forecast & Price Target

GYRE Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gyre Therapeutics Inc. is strategically positioned in the market with its acquisition of generic nintedanib, which enhances its operational capital and strengthens its leadership in therapies for idiopathic pulmonary fibrosis (IPF) as well as liver fibrosis. The company's commercial offerings, including ETUARY and its pipeline of drug candidates targeting various organ diseases, reflect a robust revenue-generating capability, particularly in the Chinese market. With a focus on innovative treatments, Gyre is set to capitalize on growing demand within the anti-inflammatory and anti-fibrotic drug segments, contributing to a positive long-term financial outlook.

Bears say

Gyre Therapeutics Inc faces a challenging outlook primarily due to depressed forward multiples reflecting current market volatility, which may impact investor confidence. The company’s commercial sales of pirfenidone in China are not included in valuation assessments, given that these revenues have plateaued and are not from growth-stage assets. Additionally, concerns regarding cash burn arise from the varying stages of development programs and the uncertainty of offsetting revenues from potential partnerships or collaborations.

GYRE has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gyre Therapeutics Inc (GYRE) Forecast

Analysts have given GYRE a Strong Buy based on their latest research and market trends.

According to 2 analysts, GYRE has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gyre Therapeutics Inc (GYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.